Strong Revenue Growth
Rhythm Pharmaceuticals reported Q3 2025 revenue of $51.3 million, a 6% sequential increase from Q2 2025. The U.S. accounted for $38.2 million (74%) and international sales contributed $13.1 million (26%).
Successful Equity Offering
The company strengthened its balance sheet with a $189 million equity offering in July 2025.
Regulatory Progress for IMCIVREE
IMCIVREE's regulatory filings for acquired hypothalamic obesity were accepted by both the FDA and EMEA, with a PDUFA date set for December 20, 2025.
Promising Data in Bardet-Biedl Syndrome
A German study showed that 80% of patients with BBS experienced improvement in steatotic liver disease or stabilization at the lowest grade after 6 months of setmelanotide therapy.